Precipio (NASDAQ:PRPO) Upgraded by Wall Street Zen to “Buy” Rating

Precipio (NASDAQ:PRPO) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Precipio has a consensus rating of “Sell”.

Precipio Stock Performance

Shares of PRPO opened at $25.40 on Friday. The company has a 50-day simple moving average of $24.93 and a 200-day simple moving average of $22.88. The company has a quick ratio of 1.10, a current ratio of 1.27 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $45.31 million, a PE ratio of -101.60 and a beta of 1.19. Precipio has a 52-week low of $3.90 and a 52-week high of $29.53.

Precipio (NASDAQ:PRPO) last announced its quarterly earnings data on Monday, March 30th. The biotechnology company reported $0.34 EPS for the quarter. Precipio had a negative net margin of 1.51% and a negative return on equity of 2.89%. The firm had revenue of $6.70 million during the quarter.

Institutional Investors Weigh In On Precipio

Large investors have recently added to or reduced their stakes in the business. AMH Equity Ltd increased its holdings in Precipio by 370.1% during the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock valued at $2,332,000 after acquiring an additional 103,210 shares in the last quarter. Topline Capital Management LLC purchased a new stake in shares of Precipio in the third quarter valued at about $1,158,000. Evernest Financial Advisors LLC acquired a new stake in shares of Precipio in the third quarter valued at approximately $374,000. Susquehanna International Group LLP acquired a new stake in shares of Precipio in the third quarter valued at approximately $194,000. Finally, Renaissance Technologies LLC increased its stake in shares of Precipio by 10.7% during the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after purchasing an additional 1,400 shares in the last quarter. 10.45% of the stock is owned by institutional investors and hedge funds.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.